Jiang, Baishan http://orcid.org/0000-0001-6796-9500
Gao, Yang
Che, Jianwei http://orcid.org/0000-0003-4956-4811
Lu, Wenchao http://orcid.org/0000-0003-1175-365X
Kaltheuner, Ines H.
Dries, Ruben http://orcid.org/0000-0001-7650-7754
Kalocsay, Marian http://orcid.org/0000-0002-4187-5829
Berberich, Matthew J.
Jiang, Jie
You, Inchul
Kwiatkowski, Nicholas
Riching, Kristin M.
Daniels, Danette L. http://orcid.org/0000-0002-7659-3020
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Geyer, Matthias
Zhang, Tinghu
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GE 976/9-2)
Article History
Received: 15 May 2020
Revised: 9 January 2021
Accepted: 4 February 2021
First Online: 22 March 2021
Competing interests
: N.S.G. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, B2S, Aduro and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Her2llc, Deerfield, Ephiphanes and Sanofi. J.C. is a consultant to Soltego, Jengu and Allorion, and equity holder for Soltego, Allorion and M3 bioinformatics & technology Inc. P.K.S. is a member of the science advisory board or board of directors of Merrimack Pharmaceutical, Glencoe Software, Applied Biomath and RareCyte Inc., and has equity in these companies. B.J., J.C., Y.G., N.K., T.Z. and N.S.G. are inventors on CDK12 degrader patents. All remaining authors declare no competing interests.